RUNX1 and acute myeloid leukemia: The RUNX1 mutation rate was higher in pDC-AML than in all AML, but RUNX1 mutations were more frequently reported in de novo AML and M0-AML in comparison with all AML and pDC-AML [155,156,157,158].